From GlobeNewswire: 2025-06-15 07:45:00

Pharmacology modeling data presented at the EAACI Congress show greater potency with verekitug compared to tezepelumab for inflammatory diseases like severe asthma, COPD, and CRSwNP. Verekitug targets the TSLP receptor for more significant treatment effects. Upstream Bio, Inc. announced these findings, supporting the differentiated profile of verekitug. The data demonstrated complete and sustained inhibition of the TSLP/TSLPR complex with verekitug, leading to a greater reduction in lung inflammation biomarkers. Phase 2 clinical trials are ongoing for severe asthma and CRSwNP, with plans for COPD trials. Verekitug is a promising treatment with a unique mechanism targeting the TSLP receptor.



Read more at GlobeNewswire: Translational Data Illustrate a Mechanism of Greater